Cargando…
Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional funct...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411701/ https://www.ncbi.nlm.nih.gov/pubmed/34484205 http://dx.doi.org/10.3389/fimmu.2021.707734 |
_version_ | 1783747342355136512 |
---|---|
author | Chasov, Vitaly Zaripov, Mikhail Mirgayazova, Regina Khadiullina, Raniya Zmievskaya, Ekaterina Ganeeva, Irina Valiullina, Aigul Rizvanov, Albert Bulatov, Emil |
author_facet | Chasov, Vitaly Zaripov, Mikhail Mirgayazova, Regina Khadiullina, Raniya Zmievskaya, Ekaterina Ganeeva, Irina Valiullina, Aigul Rizvanov, Albert Bulatov, Emil |
author_sort | Chasov, Vitaly |
collection | PubMed |
description | Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 and acquisition of new pro-oncogenic properties such as enhanced cell proliferation, metastasis and chemoresistance. Hotspot mutations of p53 are often immunogenic and elicit intratumoral T cell responses to mutant p53 neoantigens, thus suggesting this protein as an attractive candidate for targeted anti-cancer immunotherapies. In this review we discuss the possible use of p53 antigens as molecular targets in immunotherapy, including the application of T cell receptor mimic (TCRm) monoclonal antibodies (mAbs) as a novel powerful approach. |
format | Online Article Text |
id | pubmed-8411701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84117012021-09-03 Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies Chasov, Vitaly Zaripov, Mikhail Mirgayazova, Regina Khadiullina, Raniya Zmievskaya, Ekaterina Ganeeva, Irina Valiullina, Aigul Rizvanov, Albert Bulatov, Emil Front Immunol Immunology Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 and acquisition of new pro-oncogenic properties such as enhanced cell proliferation, metastasis and chemoresistance. Hotspot mutations of p53 are often immunogenic and elicit intratumoral T cell responses to mutant p53 neoantigens, thus suggesting this protein as an attractive candidate for targeted anti-cancer immunotherapies. In this review we discuss the possible use of p53 antigens as molecular targets in immunotherapy, including the application of T cell receptor mimic (TCRm) monoclonal antibodies (mAbs) as a novel powerful approach. Frontiers Media S.A. 2021-08-13 /pmc/articles/PMC8411701/ /pubmed/34484205 http://dx.doi.org/10.3389/fimmu.2021.707734 Text en Copyright © 2021 Chasov, Zaripov, Mirgayazova, Khadiullina, Zmievskaya, Ganeeva, Valiullina, Rizvanov and Bulatov https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chasov, Vitaly Zaripov, Mikhail Mirgayazova, Regina Khadiullina, Raniya Zmievskaya, Ekaterina Ganeeva, Irina Valiullina, Aigul Rizvanov, Albert Bulatov, Emil Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies |
title | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies |
title_full | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies |
title_fullStr | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies |
title_full_unstemmed | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies |
title_short | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies |
title_sort | promising new tools for targeting p53 mutant cancers: humoral and cell-based immunotherapies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411701/ https://www.ncbi.nlm.nih.gov/pubmed/34484205 http://dx.doi.org/10.3389/fimmu.2021.707734 |
work_keys_str_mv | AT chasovvitaly promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT zaripovmikhail promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT mirgayazovaregina promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT khadiullinaraniya promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT zmievskayaekaterina promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT ganeevairina promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT valiullinaaigul promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT rizvanovalbert promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies AT bulatovemil promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies |